- Georges B, Conil JM, Cougot P, et al. Cefepime in critically ill patients: continuous infusion vs an
intermittent dosing regimen. Int J Clin Pharmacol Ther 2005; 43:360–369. - Lau WK, Mercer D, Itani KM, et al. Randomized, open-label, comparative study of piperacillin-
tazobactam administered by continuous infusion versus intermittent infusion for treatment of
hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother
2006; 50:3556–3561. - McNabb JJ, Nightingale CH, Quintiliani R, et al. Cost-effectiveness of ceftazidime by continuous
infusion versus intermittent infusion for nosocomial pneumonia. Pharmacotherapy 2001; 21:549–555. - Roberts JA, Boots R, Rickard CM, et al. Is continuous infusion ceftriaxone better than once-a-day
dosing in intensive care? A randomized controlled pilot study. J Antimicrob Chemother 2007; 59:
285–291. - Sakka SG, Glauner AK, Bulitta JB, et al. Population pharmacokinetics and pharmacodynamics of
continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized,
controlled trial. Antimicrob Agents Chemother 2007; 51:3304–3310. - Van Zantan AR, Oudijk M, Nohlmans-Paulssen MK, et al. Continuous vs. intermittent cefotaxime
administration in patients with chronic obstructive pulmonary disease and respiratory tract
infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. Br J
Clin Pharacol 2007; 63:100–109. - Wysocki M, Delatour F, Faurisson F, et al. Continuous versus intermittent infusion of vancomycin in
severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents
Chemother 2001; 45:2460–2467. - Roberts JA, Lipman J, Blot S, et al. Better outcomes through continuous infusion of time-dependent
antibiotics to critically ill patients? Curr Opin Crit Care 2008; 14:390–396. - Mouton JW, Vinks AA. Continuous infusion of beta-lactams. Curr Opin Crit Care 2007; 13:598–606.
- Kasiakou SK, Sermaides GJ, Michalopoulos A, et al. Continuous versus intermittent intravenous
administration of antibiotics: a meta-analysis of randomized controlled trials. Lancet Infect Dis 2005;
5:581–589. - Lodise TP, Lomaestro B, Drusano GL. Piperacillin-tazobactam forPseudomonas aeruginosainfection:
clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007; 44:357–363. - Kim A, Sutherland CA, Kuti JL, et al. Optimal dosing of piperacillin-tazobactam for the treatment
ofPseudomonas aeruginosainfections: prolonged or continuous infusion? Pharmacotherapy 2007;
27:1490–1497. - Dandekar PK, Maglio D, Sutherland CA, et al. Pharmacokinetics of meropenem 0.5 and 2 g every
8 hours as a 3-hour infusion. Pharmacotherapy 2003; 23:988–991. - Nicolau DP. Pharmacodynamic optimization ofb-lactams in the patient care setting. Crit Care 2008;
12(suppl 4):S2–S6.
Antibiotic Kinetics in the Multiple-System Trauma Patient 535